<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04286373</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC 18 0460</org_study_id>
    <nct_id>NCT04286373</nct_id>
  </id_info>
  <brief_title>Efficacy of Non-invasive Vagus Nerve Stimulation for Treatment of Axial Spondyloarthritis Resistant to Biotherapies</brief_title>
  <acronym>EVNS-SpA</acronym>
  <official_title>Randomized Cross Over Study Assessing the Efficacy of Non-invasive Stimulation of the Vagus Nerve in Patients With Axial Spondyloarthritis Resistant to Biotherapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to demonstrate a greater proportion of patients with&#xD;
      significant improvement, according to ASAS20 definition, after 12 weeks of vagus nerve&#xD;
      stimulation (VNS) treatment than with placebo non-specific stimulation (control group).&#xD;
&#xD;
      The secondary objectives of the study are to show differences in improvement between the&#xD;
      active and placebo periods of treatment with active SNV and SNV placebo of the following&#xD;
      items:&#xD;
&#xD;
        1. Improvement according to &quot;ASAS40&quot; criteria&#xD;
&#xD;
        2. Obtaining a partial remission according to the ASAS definition&#xD;
&#xD;
        3. Improvement of BASFI&#xD;
&#xD;
        4. Decrease of C-reactive protein (CRP) serum level and erythrocytes sedimentation rate&#xD;
           (ESR),&#xD;
&#xD;
        5. Improvement of ASDAS_CRP and ASDAS_ESR&#xD;
&#xD;
        6. Difference in levels of circulating cytokines: IL-6, IL-23, IL-17, IL-33 and of matrix&#xD;
           metallopeptidases (MMP3-8-9)&#xD;
&#xD;
        7. Improvement of quality of life: assessment according to the following indexes: SF-36, AS&#xD;
           Quality of Life (ASQOL)&#xD;
&#xD;
        8. Improvement of Health Index of patient with SpA (ASAS HI) and of the Productivity at&#xD;
           Work Index (WPI)&#xD;
&#xD;
        9. Improvement of fatigue (BASDAI 1st question) and global pain&#xD;
&#xD;
       10. Improvement of Anxiety and Depression Assessment (HAD)&#xD;
&#xD;
       11. Improvement of BASMI&#xD;
&#xD;
       12. Decrease of non-steroidal anti-inflammatory drugs (NSAID) intake score.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy of non-invasive VNS therapy in patients with axial SpA has never been studied.&#xD;
      This study will assess the benefit-risk balance of the therapy through a randomized&#xD;
      double-blind cross over clinical trial.&#xD;
&#xD;
      This multi-center study will be conducted in rheumatology departments of 17 public hospitals&#xD;
      in France.&#xD;
&#xD;
      A transcutaneous vagus nerve stimulator Tens Eco 2 SCHWA MEDICO™ France will be used in this&#xD;
      study. Before the beginning of the study, a VNS practical training seminar will be organized&#xD;
      in order for all future investigators.&#xD;
&#xD;
      All patients eligible for this study must have been previously treated according to national&#xD;
      and international guidelines for patients with axial SpA. Adult patients with axial SpA&#xD;
      diagnosed and followed for at least one year, insufficiently relieved despite optimal drug&#xD;
      management, including at least two lines of biotherapies tested for at least 6 months, will&#xD;
      be enrolled in this study.&#xD;
&#xD;
      The duration of participation (treatment + follow-up) for each patient: 7 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change according to the ASAS Response Criteria (ASAS 20)</measure>
    <time_frame>At baseline and week 12</time_frame>
    <description>Assessement of efficacy of VNS treatment: for SpA patients under VNS treatment and under placebo non-specific stimulation, to demonstrate improvement of VNS treatment, according to ASAS20 definition, greater than placebo non-specific stimulation.&#xD;
ASAS20 Response is defined as follows: an improvement of 20% compared to baseline and an absolute improvement from baseline of at least 1 unit, in 3 of the 4 ASAS domains: as well as no baseline deterioration of 20% and of at least one unit in the fourth domain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement according to &quot;ASAS40&quot; criteria</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
    <description>A 40% improvement &quot;ASAS40&quot; after VNS treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial remission</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
    <description>Partial remission according to the ASAS definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of BASFI</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum CRP level</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
    <description>Changes of C-reactive protein (CRP) serum level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum ESR</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
    <description>Changes of serum erythrocytes sedimentation rate (ESR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASDAS_CRP</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
    <description>Changes of ASDAS_CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASDAS_ESR</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
    <description>Changes of ASDAS_ESR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating cytokines level of IL-6, IL-17, IL-23, IL-33, and MMP-3-8-9</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
    <description>Difference in levels of circulating cytokines: IL-6, IL-23,IL-17, IL-33 and of matrix metallopeptidases (MMP3-8-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: SF-36</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
    <description>Assessement of quality of life: according to the following indexes: SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: AS Quality of Life (ASQOL)</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
    <description>Assessement of quality of life: according to the AS Quality of Life (ASQOL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS-HI</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
    <description>Change of Health Index of patient with SpA (ASAS HI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WPI Productivity Index</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
    <description>Change of Health Index of patient with the WPI Productivity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue severity evaluation</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
    <description>A visual analogue scale (VAS) will be used to evaluate fatigue severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Pain assessment</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
    <description>Global Pain assessment will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and Depression Assessment</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
    <description>Anxiety and Depression Assessment : HAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BASMI</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-steroidal anti-inflammatory drugs (NSAID) intake score</measure>
    <time_frame>at baseline, 3 months, 4 months ans 7 months</time_frame>
    <description>Change of non-steroidal anti-inflammatory drugs (NSAID) intake score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Active stimulation then placebo stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VNS active for 12 weeks, then VNS placebo for 12 weeks.&#xD;
The VNS placebo stimulation period being the control one.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo stimulation then active stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VNS placebo for 12 weeks, then VNS active for 12 weeks.&#xD;
The VNS placebo stimulation period being the control one.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>active stimulation then placebo stimulation</intervention_name>
    <description>The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.&#xD;
VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).&#xD;
The two stimulation periods will be separated by a 4 weeks wash-out period.</description>
    <arm_group_label>Active stimulation then placebo stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>placebo stimulation then active stimulation</intervention_name>
    <description>The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.&#xD;
VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).&#xD;
The two stimulation periods will be separated by a 4 weeks wash-out period.</description>
    <arm_group_label>Placebo stimulation then active stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient with axial SpA, meeting the ASAS classification criteria, followed for&#xD;
             at least one year, with presence of radiological sacro-iliitis (ankylosing&#xD;
             spondylitis) or not;&#xD;
&#xD;
          -  Patient suffering active SpA, with or without treatment, having a total BASDAI score ≥&#xD;
             4 (0-10) at baseline and a score of global pain ≥ 4 (0-10);&#xD;
&#xD;
          -  SpA insufficiently relieved despite optimal drug management for at least 6 months&#xD;
             including at least 2 different NSAIDs at the maximum tolerated dose for at least 3&#xD;
             months (or less in case of intolerance) and at least two lines of biotherapies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under guardianship;&#xD;
&#xD;
          -  Cardiac arrhythmia;&#xD;
&#xD;
          -  Refusal to participate in the study or to sign the informed consent;&#xD;
&#xD;
          -  Pregnant or breastfeed woman;&#xD;
&#xD;
          -  No affiliation to a social security scheme;&#xD;
&#xD;
          -  Previous VNS treatment;&#xD;
&#xD;
          -  Incapacity to attend the weekly appointment during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric AZABOU, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Neurophysiology Laboratory, Department of Physiology and Functional Explorations, Raymond Poincaré Hospital, APHP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maxime Breban, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Rheumatology, Ambroise Paré Hospital, APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric AZABOU, MD, PhD</last_name>
    <phone>+ 33 1 47 10 79 40</phone>
    <email>eric.azabou@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Neurophysiology Laboratory, Department of Physiology and Functional Explorations, Raymond Poincaré Hospital, APHP</name>
      <address>
        <city>Garches</city>
        <state>Hauts-de-seine</state>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>axial spondyloarthritis</keyword>
  <keyword>vagus nerve stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

